Holen Sie sich die Stockscreener-App
67.31
8.02%
5.00
Handel nachbörslich:
67.33
0.02
+0.03%
Schlusskurs vom Vortag:
$62.31
Offen:
$62.23
24-Stunden-Volumen:
851.57K
Relative Volume:
1.35
Marktkapitalisierung:
$1.99B
Einnahmen:
$232.39M
Nettoeinkommen (Verlust:
$-26.79M
KGV:
-62.30
EPS:
-1.0804
Netto-Cashflow:
$4.41M
1W Leistung:
-0.28%
1M Leistung:
+33.63%
6M Leistung:
+48.88%
1J Leistung:
+187.04%
1-Tages-Spanne:
$60.94
$68.60
1-Wochen-Bereich:
$60.94
$68.60
52-Wochen-Spanne:
$17.11
$73.30
Anaptysbio Inc Stock (ANAB) Company Profile
Firmenname
Anaptysbio Inc
Sektor
Branche
Telefon
858-362-6295
Adresse
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
67.31 | 1.84B | 232.39M | -26.79M | 4.41M | -1.0804 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-06-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-19 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-03-12 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-02-26 | Eingeleitet | BTIG Research | Buy |
| 2024-02-21 | Eingeleitet | Stifel | Buy |
| 2024-02-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-22 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-13 | Herabstufung | Truist | Buy → Hold |
| 2022-09-01 | Eingeleitet | Raymond James | Outperform |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-03-16 | Hochstufung | Truist | Hold → Buy |
| 2021-03-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-10-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2019-11-08 | Herabstufung | SunTrust | Buy → Hold |
| 2019-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-04-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Bestätigt | Stifel | Buy |
| 2018-03-06 | Bestätigt | Stifel | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2018-01-23 | Bestätigt | Credit Suisse | Outperform |
| 2017-11-15 | Eingeleitet | SunTrust | Buy |
| 2017-11-09 | Eingeleitet | Jefferies | Buy |
| 2017-10-11 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten
(ANAB) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Analysts Are Bullish on Top Healthcare Stocks: MindWalk Holdings (HYFT), AnaptysBio (ANAB) - The Globe and Mail
UBS Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $76 - Moomoo
AnaptysBio, Inc. Financial Disclosures & Filings - TradingView
Form 144 ANAPTYSBIO For: 30 June By Investing.com - Investing.com Nigeria
[144] ANAPTYSBIO, INC SEC Filing - Stock Titan
AnaptysBio Is Maintained at Buy by UBS - Moomoo
Is AnaptysBio’s (ANAB) Index Exit and Office Sublease Quietly Reframing Its Strategic Focus? - simplywall.st
Price to book forward of AnaptysBio, Inc. – NASDAQ:ANAB - TradingView
Enterprise value to EBITDA forward of AnaptysBio, Inc. – NASDAQ:ANAB - TradingView
Form 144 ANAPTYSBIO For: 29 June By Investing.com - Investing.com Nigeria
Form DEF 14A ANAPTYSBIO For: 29 June By Investing.com - Investing.com Nigeria
Enterprise value to revenue forward of AnaptysBio, Inc. – NASDAQ:ANAB - TradingView
ANAPTYSBIO, INC ($ANAB) CEO 2025 Pay Revealed - Quiver Quantitative
Affiliate plans to sell 9,476 ANAB shares (NASDAQ: ANAB) - Stock Titan
AnaptysBio (NASDAQ: ANAB) proxy details director votes and equity plan limits - Stock Titan
Price to earnings forward of AnaptysBio, Inc. – NASDAQ:ANAB - TradingView
Price to sales forward of AnaptysBio, Inc. – NASDAQ:ANAB - TradingView
AnaptysBio, Inc.(NasdaqGS: ANAB) dropped from Russell 3000E Growth Benchmark - marketscreener.com
AnaptysBio, Inc.(NasdaqGS: ANAB) dropped from Russell 3000E Index - marketscreener.com
AnaptysBio, Inc.(NasdaqGS: ANAB) dropped from Russell Microcap Index - marketscreener.com
AnaptysBio, Inc.(NasdaqGS:ANAB) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
ANAB News | ANAPTYSBIO INC (NASDAQ:ANAB) - ChartMill
Form 144 ANAPTYSBIO For: 26 June By Investing.com - Investing.com Nigeria
ANAB (NASDAQ) insider sells 10,000 shares; Mulroy made multiple May–June sales - Stock Titan
AnaptysBio (ANAB) Draws Valuation Attention, Is The Market Already Pricing In Future Growth? - Sahm
AnaptysBio, Inc. Actuals & Estimates (NASDAQ:ANAB) - TradingView
ANAB Forecast — Price Target — Prediction for 2027 - TradingView
AnaptysBio Inc. (ANAB) Surges 4.3% as Biotech Sentiment Improves — Key Levels to WatchQuality Factor - Město Břeclav
First Tracks Biotherapeutics (NASDAQ: TRAX) subleases 45,057 sq ft in San Diego - Stock Titan
AnaptysBio (NASDAQ: ANAB) subleases San Diego facility to First Tracks under master lease - Stock Titan
AnaptysBio Inc (ANAB) Valuation: PE, PB & Fair Value Analysis - TradingKey
AnaptysBio Ord Shs (ANABV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Eversept Partners LP Takes $5.86 Million Position in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio Inc (ANAB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AnaptysBio Inc (ANAB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AnaptysBio Inc (ANAB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
AnaptysBio, Inc. $ANAB Shares Purchased by 683 Capital Management LLC - MarketBeat
AnaptysBio Inc (ANAB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AnaptysBio Inc (ANAB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AnaptysBio Inc (ANAB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AnaptysBio Inc (ANAB) Institutional Confidence - TradingKey
AnaptysBio Inc (ANAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
850-share sale notice by insider at ANAB (NASDAQ: ANAB) via Form 144 - Stock Titan
AnaptysBio (ANAB) director acquires 6,030 shares via RSU vesting - Stock Titan
Director at AnaptysBio (NASDAQ: ANAB) receives 6,030 shares via RSUs - Stock Titan
Director John Orwin of ANAPTYSBIO (NASDAQ: ANAB) settles 6,030 RSUs into common stock - Stock Titan
Granahan Investment Management LLC Reduces Holdings in AnaptysBio, Inc. $ANAB - MarketBeat
Dennis Mulroy sells multiple ANAB shares (NASDAQ: ANAB) across May–June 2026 - Stock Titan
Sofinnova Investments Inc. Has $13.95 Million Stock Position in AnaptysBio, Inc. $ANAB - MarketBeat
Daily Brief United States: SpaceX, Crude Oil, DPC Holdings, CRB Commodity Index, Vistra , AnaptysBio Inc, Kardigan, Aes Corp, GE Vernova , Biomarin Pharmaceutical and more - Smartkarma
Finanzdaten der Anaptysbio Inc-Aktie (ANAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.18%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):